SAN FRANCISCO, CA – December 12, 2023 – A groundbreaking new study, drawing on data from tens of thousands of women across the United States, is poised to fundamentally reshape the landscape of breast cancer screening. Published today in JAMA and presented concurrently at the prestigious San Antonio Breast Cancer Symposium, the research suggests that a personalized approach, meticulously tailored to a woman’s individual risk profile, is not only safer but also significantly more effective than the long-standing practice of routine annual mammograms for every woman. This pivotal shift, championed by the WISDOM study, promises to usher in an era where screening frequency is precisely matched to personal risk levels, enhancing early detection for those who need it most while potentially reducing unnecessary interventions for others.
The findings indicate a transformative potential: by adopting a comprehensive risk evaluation system, researchers observed a reduction in the likelihood of diagnosing more advanced cancers. Simultaneously, this targeted strategy ensures that individuals receive the appropriate level of screening crucial for their unique risk factors. This move away from a "one-size-fits-all" model, predominantly based on age, towards a sophisticated system integrating genetic, biological, and lifestyle factors, represents a significant leap forward in precision medicine for breast cancer prevention and early detection.
The Genesis of a Paradigm Shift: A Chronology of Screening Evolution
For decades, breast cancer screening guidelines have largely been anchored in age-based recommendations. The prevailing wisdom, solidified over the latter half of the 20th century, advocated for regular mammograms, often annually, for women starting at a certain age—typically 40 or 50. This standardized approach, while undoubtedly saving countless lives by facilitating early detection, operated on the assumption that most women faced a relatively similar risk of developing breast cancer, with age being the primary differentiating factor. However, as scientific understanding of cancer biology and genetics advanced, this simplistic model began to show its limitations. Researchers and clinicians increasingly recognized the vast heterogeneity in individual breast cancer risk, driven by a complex interplay of inherited predispositions, lifestyle choices, reproductive history, and breast tissue characteristics.
It was this growing awareness of individual variability that spurred the inception of the WISDOM study (Women Informed to Screen Depending On Measures of Risk) in 2016. Conceived as a direct, head-to-head comparison, the study aimed to rigorously evaluate whether a personalized, risk-adapted screening strategy could outperform or at least match the efficacy and safety of traditional annual mammography. The study’s architects sought to fill a critical gap in evidence, providing the robust data needed to challenge and potentially redefine established clinical guidelines. UCSF, a global leader in medical research and patient care, took on the crucial role of coordinating center for this ambitious, multi-institutional endeavor, orchestrating the enrollment and data collection from tens of thousands of participants across diverse geographical and demographic landscapes of the United States.
The first phase of the WISDOM study meticulously tracked 46,000 women, collecting extensive data on their health, genetics, and lifestyle. The culmination of years of dedicated research, data analysis, and peer review saw the study’s pivotal findings unveiled on December 12, 2023. The simultaneous publication in the esteemed journal JAMA and presentation at the San Antonio Breast Cancer Symposium—a premier global forum for breast cancer professionals—underscores the profound significance and immediate relevance of these results to the medical community worldwide. This strategic release ensures that the evidence reaches a broad audience of clinicians, researchers, and policymakers, setting the stage for imminent discussions and potential revisions of national and international screening protocols. With the initial phase yielding such compelling results, the study has now progressed to WISDOM 2.0, further refining its methodology and expanding its scope, signaling a continuous commitment to advancing personalized breast cancer care.
Unpacking the Data: The Evidence Behind Personalized Screening
The robust findings from the first phase of the WISDOM study are built upon a sophisticated methodology that directly contrasted the efficacy of traditional annual mammography with a dynamic, individualized screening strategy. Researchers meticulously grouped 46,000 participants from across the United States into distinct categories by leveraging well-validated risk models. This comprehensive assessment moved far beyond mere age, incorporating a spectrum of critical factors including genetic information, lifestyle choices, personal and family health history, and breast density. Each of these elements contributes uniquely to a woman’s overall risk profile, enabling a far more nuanced and accurate prediction of her likelihood of developing breast cancer.
Tailored Screening Recommendations:
Based on this holistic risk evaluation, participants were assigned to one of four personalized screening pathways:
- Lowest Risk Group (26% of participants): Women in this category were advised to delay routine screening until age 50, or until an advanced algorithm indicated their individual risk had naturally elevated to that of a typical 50-year-old woman. This approach aims to reduce unnecessary screening, anxiety from false positives, and cumulative radiation exposure for those least likely to benefit from early and frequent intervention.
- Average Risk Group (62% of participants): The majority of participants fell into this category, for whom screening every two years was recommended. This frequency balances the need for regular surveillance with the avoidance of over-screening, aligning with current guidelines from several major health organizations for average-risk women.
- Elevated Risk Group (8% of participants): For women identified with an elevated risk, annual mammograms were specifically recommended. This increased frequency acknowledges their higher susceptibility and aims to catch potential cancers at the earliest, most treatable stages.
- Highest Risk Group (2% of participants): This smallest but most vulnerable group received the most intensive screening regimen. Regardless of age, these women were advised to undergo screening twice a year, alternating between mammography and MRI. The inclusion of MRI, known for its superior sensitivity in dense breasts and high-risk individuals, significantly enhances the chances of detecting aggressive cancers that might be missed by mammography alone.
Crucially, the study’s findings underscored the safety and effectiveness of this personalized approach. Despite the varying screening frequencies, the personalized strategy did not lead to a higher rate of late-stage cancer diagnoses. This is a paramount indicator of success, demonstrating that reduced screening for lower-risk individuals did not compromise their health outcomes, while intensified screening for higher-risk individuals effectively prevented progression to advanced stages. Furthermore, the high acceptance rate among participants—89% of women in an observational group who chose their preferred strategy opted for risk-based screening—suggests a strong public and clinical readiness for such a change.
Beyond Screening: Personalized Prevention for Higher-Risk Women:
The WISDOM study extended its personalized approach beyond just screening frequency, incorporating tailored prevention strategies for women identified with elevated or highest risk. These participants gained access to a suite of supportive resources designed to empower them in proactively managing their breast health. This included access to an innovative online decision-making tool specifically focused on breast health, providing evidence-based information and guidance. Direct contact with a dedicated breast health specialist offered personalized counseling and support. Recommendations covered actionable lifestyle modifications, such as adopting healthier diets and increasing physical activity, both known factors in cancer risk reduction. Moreover, discussions about medications that can help lower breast cancer risk, such as selective estrogen receptor modulators (SERMs) or aromatase inhibitors, were initiated where appropriate, allowing women to make informed decisions in consultation with their healthcare providers. This holistic approach emphasizes proactive health management alongside vigilant screening.
Expanding the Frontier of Genetic Testing:
One of the most striking and potentially paradigm-shifting revelations from the WISDOM study pertains to genetic testing. Since its launch, the study has enrolled over 80,000 women and has recently expanded to include women as young as 30, specifically targeting the identification of individuals who may face an increased risk of aggressive early cancers due to inherited genetic variants.
A particularly compelling finding was that 30% of women who tested positive for a genetic variant linked to higher breast cancer risk reported no family history of the disease. Under current clinical guidelines, a significant portion of these women would typically not qualify for genetic testing, potentially leaving them unaware of their heightened risk until a cancer diagnosis. This discovery profoundly challenges the long-standing reliance on family history as the primary trigger for genetic screening, advocating for a broader, more inclusive approach.
Beyond well-known pathogenic variants like BRCA1 and BRCA2, the study also meticulously evaluated smaller DNA changes that can be integrated into a polygenic risk score (PRS). This innovative approach, combining the effects of multiple common genetic variants, significantly improved the precision of individual risk predictions. The integration of PRS resulted in 12% to 14% of participants being reassigned to a different risk category, demonstrating its power to fine-tune personalized recommendations and enhance the accuracy of risk stratification.
Allison S. Fiscalini, MPH, of UCSF, director of the Athena Breast Health Network and the WISDOM study, emphasized the significance of this aspect: "This is one of the first studies to offer genetic testing to all women, regardless of family history. When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." This statement highlights the study’s pioneering role in democratizing access to crucial genetic information, paving the way for more equitable and effective preventive strategies.
Official Voices Call for Transformative Change
The leadership behind the WISDOM study has voiced a clear and urgent call for the medical community to embrace these new findings and translate them into clinical practice. Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author, articulated the profound implications: "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice. The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." Her emphatic statement underscores the belief that the evidence is sufficiently compelling to necessitate a fundamental overhaul of existing protocols, moving towards a more proactive and tailored patient care model. Dr. Esserman’s vision extends beyond mere screening; she sees comprehensive risk assessment as the gateway to effective, individualized prevention, allowing healthcare providers to intervene earlier and more strategically.
Co-author Jeffrey A. Tice, MD, a UCSF professor of Medicine specializing in breast cancer risk assessment tools, echoed this sentiment, emphasizing the practical and resource-management benefits. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," Dr. Tice stated. This perspective highlights not only the clinical advantages of improved detection and prevention but also the potential for optimizing healthcare expenditures and minimizing the societal burden associated with over-screening and late-stage diagnoses. By focusing intensive resources on those who stand to benefit most, the healthcare system can achieve greater impact with finite resources.
The multi-institutional nature of the WISDOM study, with UCSF serving as the coordinating center and collaborations extending across numerous academic and clinical institutions—including UC Los Angeles, UC Irvine, UC San Diego, Sanford Health, the University of Chicago, and others—lends significant weight to its findings. This broad collaboration ensures the generalizability of the results across diverse patient populations and healthcare settings, reinforcing the study’s credibility and the widespread applicability of its conclusions. The collective expertise and shared commitment to advancing breast cancer care from such a wide array of investigators solidify the study’s position as a landmark achievement in medical research.
The medical community, including major professional organizations and public health agencies, is now faced with the imperative to critically evaluate these findings. While changes to established guidelines are typically deliberate and require consensus, the compelling data from WISDOM are expected to ignite vigorous discussions. Patient advocacy groups are also likely to champion this personalized approach, seeing it as a means to empower women with more precise information about their health and to reduce the physical and psychological burdens associated with unnecessary or inappropriate screening. The official responses from leading researchers indicate a strong conviction that the era of universal breast cancer screening guidelines is nearing its end, making way for a future defined by personalized, data-driven care.
The Far-Reaching Implications of Personalized Screening
The WISDOM study’s findings carry profound implications that extend across clinical practice, public health policy, and the patient experience, promising a significant paradigm shift in breast cancer care.
For Clinical Practice:
The most immediate implication is the need for healthcare providers to adopt comprehensive risk assessment as a standard component of breast cancer screening decisions. This will require new tools and protocols for collecting and integrating diverse data points, including genetic information, detailed health histories, lifestyle factors, and breast density. Clinicians will need training in interpreting polygenic risk scores and effectively communicating complex risk information to patients. The implementation of personalized screening will demand a more nuanced consultation process, moving beyond simple age-based recommendations to a shared decision-making model where patients are actively involved in choosing their screening frequency based on their individual risk profile. Challenges may arise in the initial stages regarding the accessibility of advanced genetic testing and the integration of risk assessment models into electronic health records.
For Patients:
The personalized approach offers several crucial benefits for women. For those at lower risk, it means potentially reducing the frequency of mammograms, thereby decreasing anxiety associated with screening, minimizing false positives, and lowering cumulative radiation exposure. For women at elevated or highest risk, it ensures more vigilant and appropriate screening, including the use of advanced modalities like MRI, leading to earlier detection of potentially aggressive cancers. Crucially, the personalized prevention strategies, including lifestyle guidance and discussions about risk-reducing medications, empower women to take a more active and informed role in managing their breast health. This tailored approach fosters a sense of agency and reduces the distress associated with generic, sometimes ill-fitting, medical advice.
For Public Health Policy and Insurance:
The study’s results will undoubtedly exert significant pressure on major public health organizations, such as the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF), to review and update their breast cancer screening guidelines. Policy revisions will need to consider the economic implications of broader genetic testing and varied screening frequencies. Insurance providers will face demands to cover comprehensive risk assessments, including genetic testing and advanced imaging like breast MRI, for individuals identified as high-risk, regardless of prior family history. The long-term societal benefit of shifting resources from lower-risk women to higher-risk women could lead to more efficient allocation of healthcare dollars, potentially reducing the overall cost of treating advanced cancers.
Future Research and Broader Impact:
The journey doesn’t end with WISDOM’s initial findings. Researchers are already forging ahead with the WISDOM 2.0 study, which is actively enrolling participants. The primary goal of this next phase is to further refine risk assessment methodologies, particularly in identifying women who face a higher likelihood of developing aggressive breast cancers. This ongoing research aims to provide even more precise screening and prevention strategies tailored to long-term health needs, ensuring continuous improvement in personalized medicine.
Beyond breast cancer, the WISDOM study’s success could serve as a powerful model for other cancer screenings and preventive health initiatives. Its methodology—integrating genetic, biological, and lifestyle factors to create individualized risk profiles—could be adapted to diseases such as colorectal cancer, lung cancer, or prostate cancer, paving the way for a future where preventive care across the spectrum of human health is truly personalized and optimized for every individual. The comprehensive, data-driven approach exemplified by WISDOM represents a significant stride towards a future of precision prevention, promising safer, more effective, and more equitable healthcare for all.
Co-Authors and Institutions: The extensive list of co-authors from UCSF includes Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.
Additional investigators are affiliated with UC Los Angeles; UC Irvine; UC San Diego; San Francisco VA Health Care System; Sanford Health in North Dakota; University of Chicago; Diagnostic Center of Miami; University of Alabama; Virginia Commonwealth University; Weill Cornell Medicine in New York; and the Karolinka Institutet in Stockholm.
Funding: The WISDOM study received crucial support from the Patient-Centered Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation, among other contributing sources detailed in the published paper.
Conflicts of Interest: Dr. Esserman serves as a medical advisory panel member for Blue Cross Blue Shield and has received author fees from the UpToDate electronic medical information resource. Comprehensive disclosures for all investigators are available in the full research paper.
About the Author
